MHLW 2009 Budget Requests ¥1.4 Billion To Strengthen PDMA Safety Measures
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare released Aug. 26 a budget request for fiscal year 2009 of ¥22.85 trillion, an ¥829.2 billion and 3.8 percent increase compared to FY 2008's initial budget. The budget allocates ¥48.2 billion to stock up on flu drugs such as Tamiflu (oseltamivir)and Relenza (zanamavir) and pre-pandemic vaccines, and to develop pandemic vaccines. ¥33.2 billion is designated to develop new drugs in the areas of cancer, mental disorder, intractable and rare diseases and regenerative medicine. To boost safety measures in drugs and medical devices, ¥1.4 billion is allocated to the Pharmaceutical and Medical Device Agency to increase staff, and ¥900 million to the PDMA in establishing a consulting system to promote Japan-U.S.-Europe joint clinical trials and concurrent reviews for medical device. (Click here for more - Japanese language
You may also be interested in...
Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs
TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.